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Abstract
Background: The role of radiolabeled choline (Cho) in patients with biochemical recurrence after radical treatment
for prostate cancer (PCa) is well established. Its widespread clinical use has prompted the depiction of
incidentalomas, unusual sites of metastatic lesions, as well as false positive and negative cases. We reported a series
of patients affected by biochemical recurrence of PCa imaged by [18F]Cho positron emission tomography/
computed tomography (PET/CT) which resulted suspected for a second malignancy.
Case presentation: [18F]Cho PET/CT was performed in patients with biochemical PCa recurrence. From an internal
clinical database we identified patients in which PET/CT resulted suspected for a second malignancy. A second
malignancy was suspected in presence of “unusual” site of [18F]Cho uptake not consistent with clinical-instrumental
history. Histology was used as reference standard for final diagnosis.
Seven PCa patients (76 years, 71–84 years) with the suspicion of a second tumor based on [18F]Cho PET/CT findings
were identified. Mean value of PSA at the time of [18F]Cho PET/CT was 2,37 ng/mL. The median time between PCa
diagnosis and PET/CT was 6 years (range 0–14 years). In two cases history of a second malignancy (lung cancer and
cutaneous basocellular carcinoma) was known (diagnosed 12 and 6 years after PCa, respectively). PET/CT identified 13
sites of [18F]Cho uptake (lung = 5, lymph node = 7, bone = 1). Final diagnosis was consistent with lung cancer in 5/7
cases (first diagnosis = 4/5, recurrence = 1/5), colorectal cancer and nodal metastases from melanoma in 1 case each.
Conclusions: Although the clinical usefulness of Cho PET/CT for detecting cancer lesions other than prostate origin is
known, for those patients who undergo this examination according to indication, the diagnosis of a second tumor has
a significant impact on their therapeutic management.
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Background
Prostate cancer (PCa) is a clinically heterogeneous
disease characterized by an overall long natural history
in comparison with other solid tumors, showing a wide
spectrum of biological behavior ranging from indolent
to aggressive [1]. Despite highly successful treatments
for localized prostate cancer, approximately 15–40 % of
patients will experience a detectable rise in the serum
prostate specific antigen (PSA) level (i.e. biochemical
failure) within 10 years after primary treatment [2]. In
patients with biochemical failure, imaging plays a critical
role in distinguishing between local recurrence and
distant spread of disease when developing appropriate
treatment strategies [3]. The biochemical process target
of choline-based tracers is the synthesis of cell mem-
brane [4]. The uptake of radiolabeled choline would
reflect the proliferative activity by estimating membrane
lipid synthesis. Tumor cells with high proliferation rate,
will have high uptake of choline to keep up with in-
creased demands for the synthesis of phospholipids [5].
Based on these premises and the need of radiotracer alter-
native to [18F]fluorodeoxyglucose to image some neo-
plasms, starting from 1970s radiolabeled choline was
introduced as positron emission tomography tracer to
image brain tumor and PCa [6, 7]. Radiolabeled choline
(Cho) positron emission tomography/computed tomog-
raphy (PET/CT) has been widely investigated as diagnos-
tic tool to restage PCa in case of biochemical recurrence
and has been shown to be of value in the detection of local
recurrence and distant metastases [8]. It has been shown
that in almost 50 % of patients, choline PET/CT findings
impact on patient’s management [8, 9]. However, choline
PET/CT may also be successfully used to image a variety
of other malignancies [8, 10–13]. As for many other
tumors, also in PCa, the detection of a second malignancy
really change the management of the patient and the
treatment strategies [14].
In this paper, we addressed the added value of fluorocho-
line ([18F]Cho) PET/CT in PCa patients to identify a second
malignancy underlying the need of a proper expertise in the
interpretation of the images.
Case presentation
We reported in the present series seven PCa patients
selected from an internal clinical database, in whom
based on [18F]Cho PET/CT results, a second malignancy
was suspected. All patients were referred to the Nuclear
Medicine Unit to perform a fluorocholine PET/CT. All
patients presented a biochemical PCa recurrence at the
time of [18F]Cho PET/CT. The suspicious of a second
malignancy was supposed based on PET/CT findings
(i.e. “unusual” site of [18F]Cho uptake not consistent
with clinical-instrumental history) according to previ-
ously reported by Calabria et al. [11].
Images were acquired using a dedicated PET/CT
tomograph (Discovery, GE or Gemini, Philips). In our
experience the prevalence of a diagnosis of a second
malignancy detected by [18F]Cho PET/CT in PCa pa-
tients was 0.53 %. All patients provided informed
consent for PET/CT examination and for the use of
personal data. Baseline patients characteristics and main
results are detailed in Table 1.
Case #1
A 72-yr old man affected by PCa was treated by radical
prostatectomy (2004) and androgen deprivation therapy
(ADT) (ongoing) presented in 2010 PSA raising
(0.11 ng/mL) and pain localized at pelvis and left leg. An










Year Clinical purpose [18F]Fluorocholine
uptake (site)
Expected Undertaken
#1 72 RP (2004) + ADT
(ongoing)
0.11 2010 Diagnosis of incidental







#2 71 RP (1998) + salvage
EBRT (2009)
0.08 2010 Persistence of increased
PSA after salvage EBRT
Lung NSCLC ADT CHT (platinum-based)










#5 71 EBRT (2003) + ADT
(stopped)
3.16 2012 Biochemical recurrence Lung NSCLC Salvage EBRT Lung lobectomy + salvage
EBRT
#6 74 RP (2012) 1.4 2012 Persistence of increased
PSA after RP
Lung NSCLC ADT Lung lobectomy + salvage
EBRT
#7 80 RP (2012) + ADT
(stopped)






ADT androgen deprivation therapy, EBRT external beam radiation therapy, CHT chemotherapy, NSCLC non small cell lung cancer, PCa prostate cancer, PSA prostate
serum antigen, Pt patient, RP radical prostatectomy
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enhanced computed tomography (CT) scan of the abdo-
men identified a lesion of the left ischium involving the
neighboring soft tissues. In the clinical suspicion of a
PCa metastases, a [18F]Cho PET/CT was required. PET/
CT detected tracer uptake in a peri-hilar right lung nod-
ule (SUVmax = 3.9) and in the known left pelvic lesion
(SUVmax = 6.6) (Fig. 1). The biopsy of the right lung
nodule diagnosed a non small cell lung cancer (NSCLC),
while that of the bone metastases was inconclusive
(metastases from adenocarcinoma of unknown origin
resulting positive for both cheratin and AE1/AE3 and
negative for both TTF1 and PSA). Based on histological
findings the patient started platinum-based chemother-
apy plus palliative external beam radiation therapy
(EBRT) for the bone metastases.
Case #2
A 71-yr old man was treated with radical prostatectomy
(1998) for PCa and subsequently with salvage EBRT (2009)
for local recurrence. In 2010 he underwent a right lung lob-
ectomy for a NSCLC (pT1N0M0). After salvage EBRT,
PSA value although decrease, was not void (0.08 ng/mL)
and a restaging [18F]Cho PET/CT was performed. PET/CT
identified an area of [18F]Cho uptake in a small nodule of
Fig. 1 Case#1, 72-yr old man with prostate cancer treated with radical prostatectomy with radiological evidence of bone metastasis. [18F]fluorocholine
PET/CT shows tracer uptake in the peri-hilar right lung region (a, MIP arrow) and in the left side of the pelvis. Transaxial images (b) confirm a
metabolically active area in a peri-hilar right lung nodule subsequently diagnosed as non small cell lung cancer. Superimposed transaxial PET/CT
images (c, bone window; d, soft tissue window) show [18F]fluorocholinee uptake in a vast metastatic lesion involving the left pubis, the left ischium
and extending into the adjacent soft tissues. Bone metastases biopsy resulted inconclusive (metastases from adenocarcinoma of unknown origin)
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the right lung (SUVmax = 2.7, Fig. 2). Biopsy was performed.
The final diagnosis was consistent with NSCLC recurrence
and a platinum-based chemotherapy was started.
Case #3
A 84-yr old man was treated with EBRT with curative
intent (1996) for PCa and with surgery for a basocellular
cancer of the skin (2001). Recently PSA values increased
up to 2.62 ng/mL. He was symptomless. In order to
chose the best treatment option (ADT +/− salvage
EBRT) a [18F]Cho PET/CT was required. [18F]Cho PET/
CT identified tracer uptake in a left lung nodule (SUV-
max = 5.1) and in some hilar-mediastinal lymph nodes
(SUVmax = 3.3-4) as shown by Fig. 3. PET/CT findings
were confirmed by histology which diagnosed a NSCLC
with lymph nodes metastases. Despite the diagnosis, the
patient based on his good clinical condition and the age,
refused any type of treatment for NSCLC, including
surgery and chemotherapy. Any treatment for PCa has
not been taken avoiding possibly side effects since the
prognosis of NSCLC with lymph nodes metastases, was
considered the driver for the therapeutic decision.
Case #4
A 80-yr old man was treated with radical prostatectomy
(2003) for PCa and more than 10 years later PSA
increased up to 8.77 ng/mL. He was symptomless and in
good clinical condition. In order to chose the best treat-
ment option (ADT +/− salvage EBRT) a [18F]Cho PET/
CT was required. PET/CT identified the presence of an
area of [18F]Cho uptake in a left supraclavicular lymph-
adenopathy (SUVmax = 15). Patient was also scanned
with [18F]FDG-PET/CT which confirmed the finding
(SUVmax = 43; Fig. 4). Subsequently was performed an
excisional biopsy which diagnosed melanoma metasta-
ses. The patient had no melanoma’s history. Hence he
underwent clinical examination and he repeated a
[18F]FDG-PET/CT in order to diagnose the primary site
of the melanoma which resulted both negative. Consid-
ering the prognosis quod vitam more linked to melan-
oma than PCa, it was not taken into account any
therapy for PCa and the patients was candidate only to
follow-up.
Case #5
A 71-yr old man with PCa treated by EBRT with cura-
tive intent (2003) and ADT (stopped in 2008) presented
in 2012 increase in PSA value (3.16 ng/mL). The PET/
CT performed for the identification of the site of disease
relapse during biochemical recurrence, revealed an area
of [18F]Cho uptake in a left lung nodule. The biopsy
diagnosed a NSCLC. Based on PET/CT findings the
patient was treated by left lobectomy for NSCLC.
Salvage EBRT on prostatic bed was also performed.
Case #6
A 74-yr old man was treated with radical prostatectomy
(2014) for PCa. However, PSA remained high after
surgery reaching a nadir of 1.4 ng/mL. In order to
restage the disease and chose the best treatment option,
Fig. 2 Case#2, 71-yr old man presenting raising PSA values after radical surgery for prostate cancer. The patient was also surgically treated
for lung cancer. MIP (a) and axial (b) [18F]fluorocholine PET/CT images show an area of focal radiopharmaceutical uptake in the right lung,
subsequently proven to be non small cell lung cancer
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a [18F]Cho PET/CT was performed. PET/CT identified
the presence of an area of [18F]Cho uptake in a right
lung nodule subsequently diagnosed as NSCLC. Hence
he underwent lung lobectomy plus salvage EBRT on
prostatic bed and follow-up without any evidence of
recurrence for both prostate and lung cancers.
Case #7
A 80-yr old man was treated with radical prostatectomy
in November 2012 for PCa. In 2013 PSA started to
increase up to 0.3 ng/mL. In order to chose the best
treatment option (ADT +/− salvage EBRT) the patient
underwent a [18F]Cho PET/CT which identified the
Fig. 3 Case#3, 84-yr old man treated with radiation therapy for prostate cancer and with surgery for a basocellular cancer of the skin, presenting
with increased PSA values. MIP (a) and fused [18F]fluorocholine PET/CT axial (b) images show increased radiopharmaceutical uptake in the left
lung and in multiple hilar and mediastinal lymph nodes subsequently diagnosed as non small cell lung cancer with lymph nodes metastases
Fig. 4 Case #4, 80-yr old man treated with radical prostatectomy for prostate cancer, presenting with progressive PSA raise. MIP (a), axial and
coronal (b) [18F]fluorocholine PET/CT images show an area of intense [18F]fluorocholine uptake in a left supraclavicular lymph node. The patient
underwent a [18F]FDG-PET/CT, that confirms the finding as shown by MIP images (c), transaxial and coronal images (d). Biopsy diagnosed a nodal
metastases from melanoma
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presence of a “hot spot” of [18F]Cho in the rectum
(SUVmax = 7.6, Fig. 5) which was subsequently diagnosed
as colorectal cancer. The patient was surgically treated
with anterior resection of rectum and then he started
ADT for PCa recurrence.
Discussion
Our results confirm the ability of [18F]Cho PET/CT to
identify tumor lesion(s) other than PCa. Nevertheless, in
PCa patients it may be difficult to distinguish between PCa
metastasis and other malignancies. The possibility of “pit-
falls” in the interpretation of radiolabeled choline PET/CT
imaging in PCa has been reported by Calabria et al. [11]
who demonstrated that a careful evaluation of the CT com-
ponent of images associated to a complete clinical and in-
strumental data analysis, and eventually to histology,
should be always performed to establish a correct diagnosis.
In our series, focal choline uptake was found in all cases,
however the site and the characteristics of the uptake were
not considered “usual” for PCa metastases resulting more
suggestive for lesion of other origin with the exception of
the patient (#1) who had bone metastases. In this specific
case, histology concluded for a bone metastases from
adenocarcinoma but it wasn’t able to discriminate its origin
(NSCLC versus PCa). Anyway in this specific case NSCLC
diagnosis has driven the therapeutic decision since its prog-
nosis is worst than PCa. In the majority of our cases, the
Cho uptake was localized in the lung. These findings may
be explained by looking of incidence of cancers. According
to International Agency for Research on Cancer [15] the
five most frequent cancers in men in Italy are PCa (23.2 %),
lung (14 %), colorectal (13.8 %), bladder (7.6 %), and kidney
(4 %). Differently from what was reported by Calabria et al.
[11] final diagnosis in all our cases was consistent with
NSCLC. Anyway, patients included in this series, had not a
known lung nodule in their medical history and the
[18F]Cho uptake registered in the lung nodule was higher
than that reported by Calabria et al. (mean SUVmax = 3.9
versus 2.2) [11]. Similarly the [18F]Cho uptake in lymph
nodes was not due to inflammation, but it was related to
NSCLC (#3) and melanoma (#4) metastases, respectively.
In literature we did not find any case of melanoma previ-
ously imaged by [18F]Cho PET/CT. Noteworthy in this spe-
cific case, PSA was relatively high (8.77 ng/mL) and the
hypothesis of a nodal metastases from PCa was realistic
despite the site (supraclavicular) was considered unusual
and therefore was decided to go on with biopsy. As recently
pointed out by How Kit et al. [16], doubtful lesions should
be always biopsied. They reported a large series of patients
with rising PSA and known or suspected second malig-
nancy imaged by [18F]FDG and [18F]Cho PET/CT. Anyway,
they found that [18F]Cho/[18F]FDG SUVmean ratio cannot
differentiate PCa recurrences from other cancer types
concluding that when both diagnoses are suspected, lesions
should be biopsied. In our series, only one patient was
imaged using both [18F]FDG and [18F]Cho PET/CT. The
Fig. 5 Case#7, [18F]fluorocholine PET/CT in a 80-yr old man treated with increased PSA after radical prostatectomy for prostate cancer. MIP (a)
and axial (b) image show a metabolically active area in the rectum which was subsequently diagnosed as colorectal adenocarcinoma (pT3N0)
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availability of this information for only one patient, pre-
cluded any further comment. Moreover, PET/CT images
were acquired using different scanners, affecting
comparability of SUVmax. However, SUVmax was reported
to provide trough a simple index, the degree of tracer up-
take as well as to compare our findings to literature data,
but it was not used for diagnostic purpose.
Differently from that reported by Garcia et al. [14], in
all our cases [18F]Cho PET/CT resulted positive, impact-
ing on patients’ management, although any PCa recur-
rence wasn’t identified.
The detection rate of choline PET, reported in literature
in the restaging phase, varies between 21 and 82 %, mainly
depending on the site of recurrence and PSA levels (detec-
tion rate >50 % in case of a median PSA level of 2 ng/ml;
detection rate <30 % in case of a PSA level of < 1 ng/ml)
[17]. In the setting of PSA relapse after local therapy differ-
ent treatment strategies can be chosen either salvage EBRT
alone or in combination with anti-androgen therapy or
anti-androgen therapy alone [18]. The latter option is ap-
plied in a palliative intent and should be considered in pa-
tients with bad performance status, patients with high PSA
values (>2 ng/mL) with a high risk of metastatic disease or
in patients where salvage radiotherapy cannot be carried
due to other reasons (e.g., previous pelvic EBRT) [19]. In
this series of patients, the biochemical PCa recurrence was
manage according to the standard of care (EBRT or ADT)
with some exceptions. Nonetheless, in all patients the
therapeutic approach was modified or implemented based
on PET/CT results. In the patient #1 who was candidate
to chemotherapy, the regimen adopted was completely
different after the diagnosis of NSCLC compared to what
would had been used in the case of PCa metastases (plat-
inum-based versus docetaxel) [20, 21]. In the patient #2
clinicians decided for a watch and wait, postponing the
initiation of the ADT due to the relative low PSA level
and the negativity of [18F]Cho PET/CT for PCa recur-
rence. The patient #3 refused any treatment, while in the
patient #4 the prognosis of melanoma drove the thera-
peutic decision. In all other cases, the change of manage-
ment included chemotherapy or surgery (+/− EBRT)
instead of ADT and/or salvage EBRT alone.
Anyway, as previously pointed up [11, 22, 23], reading a
radiolabeled Cho PET/CT, it should take into account the
pharmacokinetic and the biodistribution of the radiophar-
maceutical as well as the possibility of pitfalls (e.g.
parathyroid or thyroid adenomas [24, 25], bilateral hilar-
mediastinal lymph nodes [11], Fig. 6) since if it is true that
the diagnosis of a second malignancy impacts on patients’
management [14], it is more true that unnecessary
procedures and examinations should be avoided in cancer
patients unless a very high suspicion.
Conclusion
To conclude, as previously reported our findings are
consistent with the possibility of choline uptake in
malignant lesion(s) other than PCa metastases and con-
firm the needed to accurately ensure any possible “un-
usual” site of choline uptake of the tracer by histology in
order to exclude the presence of a concomitant
malignancy.
Fig. 6 Examples of pitfalls at [18F]fluorocholine PET/CT in presence of inflammation. Mild [18F]fluorocholine uptake might be present in reactive
lymph nodes as shown in these patients (not included in the present series but reported as examples) who present along with prostate lodge
recurrence from prostate cancer increased [18F]fluorocholine uptake in reactive cervical lymph node (a, MIP arrow) and bilateral axillary and hilar/
mediastinal lymph nodes (b, MIP and PET coronal arrows)
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